SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis

BioScience Trends

Volumn 7, Issue 5, 2013, Pages 237-244

  Qin, Yizhuo ^a   Lu, Yuyin ^a   Wang, Ruiqi ^a   Li, Wenbao ^b   Qu, Xianjun ^a  

^a SHANDONG UNIVERSITY   (China)

^b Sanlugen Pharma Tech   (China)

Author keywords

Antiangiogenesis; Human hepatocellular carcinoma; Multi kinase inhibitor; SL1122 37; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; SORAFENIB;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; COLORIMETRY; DRUG EFFECT; HUMAN; LIVER CELL CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORIMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84888424712     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.5.237     Document Type: Article

References (21)

1. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5:835-844.
2. Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon K, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013; 27:555-561.
3. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis, Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol. 2008; 9:117-123.
4. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24:1363-1369.
5. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855-867.
6. Li WB. The design and synthesze of anti-cancer agent belong to indazole or azaindazole based diarylureas or diarylsulfoureas, China patent (2012), CN 102153551B.
7. Zhu T, Jiao Y, Chen YD, Wang X, Li HF, Zhang LY, Lu T. Pharmacophore identification of Raf-1 kinase inhibitors. Bioorg Med Chem Lett. 2008; 18:2346-2350.
8. Cui CZ, Wen XS, Cui M, Gao J, Sun B, Lou HX. Synthesis of solasodine glycoside derivatives and evaluation of their cytotoxic effects on human cancer cells. Drug Discov Ther. 2012; 6:9-17.
9. Bommareddy A, Zhang XY, Kaushik RS, Dwivedi C. Effects of components present in flaxseed on human colon adenocarcinoma Caco-2 cells: Possible mechanisms of flaxseed on colon cancer development in animals. Drug Discov Ther. 2010; 4:184-189.
10. Zamri N, Masuda N, Oura F, Yajima Y, Nakada H, Fujita-Yamaguchi Y. Effects of two monoclonal antibodies, MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor, on the growth of colon cancer cells. Biosci Trends. 2012; 6:303-312.
11. Sun NK, Huang SL, Chang TC, Chao CC. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation. J Cell Biochem. 2013; 114:1819-1831.
12. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009; 69:3927-3936.
13. Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013; 43:147-154.
14. Li G, Zhang S, Fang H, Yan B, Zhao Y, Feng L, Ma X, Ye X. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1. Biochem Biophys Res Commun. 2013; 434:809-814.
15. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010; 126:2426-2436.
16. Perkins ND. Integrating cell-signalling pathways with NF- κB and IKK function. Nat Rev Mol Cell Biol. 2007; 8:49-62.
17. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001; 107:3-6.
18. Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol. 2013; 7:87-102.
19. Zhang YS, Xie JZ, Zhong JL, Li YY, Wang RQ, Qin YZ, Lou HX, Gao ZH, Qu XJ. Acetyl-11-keto-β-boswellic acid (AKBA) inhibits human gastric carcinoma growth through modulation of the Wnt/β-catenin signaling pathway. Biochim Biophys Acta. 2013; 1830:3604-3615.
20. Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y, Lu J. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem. 2013; 381:139-144.
21. Inagaki Y, Tang W, Zhang L, Du GH, Xu WF, Kokudo N. Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. Biosci Trends. 2010; 4:56-60.